NO EVIDENCE OF A MORE AGGRESSIVE PATTERN OF HEPATOCELLULAR CARCINOMA AFTER DIRECT ACTING ANTIVI-RALS -RESULTS FROM A SINGLE CENTER OBSERVATIONAL STUDY

https://www.doi.org/10.22551/MSJ.2021.01.07

  • MUZICA Cristina-Maria “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • TRIFAN Anca “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • GIRLEANU Irina “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • HUIBAN Laura “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • PETREA Oana Cristina “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • SINGEAP Ana Maria “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • COJOCARIU Camelia “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • ZENOVIA S. “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • CUCIUREANU T. “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • NASTASA R. “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • STANCIU C. “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Abstract

After great concerns were raised regarding a high incidence of hepatocellular carcinoma (HCC) after direct acting antivirals (DAAs) therapy in cirrhotic HCV patients, an avalanche of studies that debated this issue emerged, whose results highlighted also a more aggressive HCC pattern after DAAs. We aimed to assess the pattern and imaging features of HCC in patients with HCV-related liver cirrhosis after DAAs. Material and methods: This is a single-center case-controlled retrospective study in which we included consecutive patients with HCC and HCV-related liver cirrhosis admitted in our clinic between January 1st, 2016 and May 1st, 2018. Results: Sixty-nine patients with HCV-related cirrhosis and HCC were divided into 2 groups depending on the DAAs-treated or untreated status: group I included 15 patients that were previously treated with DAAs and group II included 54 naïve patients. Regarding the distribution of HCC, there were no significant differences between the two groups (73.3% of group I patients and 55.5% of group II had unicentric lesion, p=0.215). The tumor size was significantly higher in group II compared to group I, with 66.6% of patients in group I and only 29.6% of patients in group II that have a tumor size less than 3 cm (p=0.009). Supportive treatment without ablation was more frequent in group II (33.3%) than in group I (6.6%) (p=0.047). Conclusions: Our study found no evidence of a more aggressive behavior of HCC after DAAs treatment compared to naïve patients. Furthermore, the pattern of HCC after DAAs did not affect the access to curative treatment.

Author Biographies

MUZICA Cristina-Maria, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Medical Specialties (I)
“Sf. Spiridon” County Clinical Emergency Hospital Iasi, Romania
Institute of Gastroenterology and Hepatology

TRIFAN Anca, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Medical Specialties (I)
“Sf. Spiridon” County Clinical Emergency Hospital Iasi, Romania
Institute of Gastroenterology and Hepatology

GIRLEANU Irina, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Medical Specialties (I)
“Sf. Spiridon” County Clinical Emergency Hospital Iasi, Romania
Institute of Gastroenterology and Hepatology

HUIBAN Laura, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Medical Specialties (I)
“Sf. Spiridon” County Clinical Emergency Hospital Iasi, Romania
Institute of Gastroenterology and Hepatology

PETREA Oana Cristina, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Medical Specialties (I)
“Sf. Spiridon” County Clinical Emergency Hospital Iasi, Romania
Institute of Gastroenterology and Hepatology

SINGEAP Ana Maria, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Medical Specialties (I)
“Sf. Spiridon” County Clinical Emergency Hospital Iasi, Romania
Institute of Gastroenterology and Hepatology

COJOCARIU Camelia, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Medical Specialties (I)
“Sf. Spiridon” County Clinical Emergency Hospital Iasi, Romania
Institute of Gastroenterology and Hepatology

ZENOVIA S., “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Medical Specialties (I)
“Sf. Spiridon” County Clinical Emergency Hospital Iasi, Romania
Institute of Gastroenterology and Hepatology

CUCIUREANU T., “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Medical Specialties (I)
“Sf. Spiridon” County Clinical Emergency Hospital Iasi, Romania
Institute of Gastroenterology and Hepatology

NASTASA R., “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Medical Specialties (I)
“Sf. Spiridon” County Clinical Emergency Hospital Iasi, Romania
Institute of Gastroenterology and Hepatology

STANCIU C., “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Medical Specialties (I)
“Sf. Spiridon” County Clinical Emergency Hospital Iasi, Romania
Institute of Gastroenterology and Hepatology

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424.
2. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118-1127.
3. Global hepatitis report 2017. Geneva: World Health Organization; 2017.
4. Muzica CM, Stanciu C, Huiban L, et al. Hepatocellular carcinoma after direct-acting antiviral hepatitis C virus therapy: A debate near the end. World J Gastroenterol 2020; 26(43): 6770-6781.
5. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584-2593.
6. Reig M, Mariño Z, Perelló C, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol 2016; 65: 719-726.
7. Conti F, Buonfiglioli F, Scuteri A, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol 2016; 65: 727-733.
8. Backus LI, Belperio PS, Shahoumian TA, Mole LA. Impact of sustained virologic response with direct-acting antiviral treatment on mortality in patients with advanced liver disease. Hepatology 2019; 69: 487-497.
9. Ioannou GN, Green PK, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol 2018; 68: 25-32.
10. Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, El-Serag HB. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology 2017; 153: 996-1005.
11. Renzulli M, Buonfiglioli F, Conti F, et al. Imaging features of microvascular invasion in hepatocellular carcinoma developed after direct-acting antiviral therapy in HCV-related cirrhosis. Eur Radiol 2018; 28(2): 506-513.
12. Abdelaziz AO, Nabil MM, Abdelmaksoud AH, et al. Tumor behavior of hepatocellular carcinoma after hepatitis C treatment by direct-acting antivirals: comparative analysis with non-direct-acting antivirals-treated patients. Eur J Gastroenterol Hepatol 2019; 31(1): 75-79.
13. El Fayoumie M, Abdelhady M, Gawish A, et al. Changing Patterns of Hepatocellular Carcinoma after Treatment with Direct Antiviral Agents. Gastrointest Tumors 2020; 7: 50-60.
14. Khalid J, Umar M, Ur-Rehman T, Ali M, Khan GM. Tumor aggression among hepatitis-C related hepatocellular carcinoma patients: an observational study regarding the impact of anti-HCV therapy. Infect Agents Cancer 2020; 15: 1-13.
15. Fatima T, Mumtaz H, Khan MH, et al. Patterns of Hepatocellular Carcinoma after Direct Antiviral Agents and Pegylated-Interferon Therapy. Cureus 2020; 12(11): e11565.
Published
2021-03-30
Section
INTERNAL MEDICINE - PEDIATRICS